1. Home
  2. BEAM vs OUST Comparison

BEAM vs OUST Comparison

Compare BEAM & OUST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$26.87

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Logo Ouster Inc.

OUST

Ouster Inc.

N/A

Current Price

$29.51

Market Cap

2.2B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
OUST
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
BEAM
OUST
Price
$26.87
$29.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
6
Target Price
$49.38
★ $59.40
AVG Volume (30 Days)
1.8M
★ 2.3M
Earning Date
11-10-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.31
48.56
EPS
N/A
★ N/A
Revenue
$24,000.00
★ $169,384,000.00
Revenue This Year
N/A
$30.78
Revenue Next Year
$14.48
$35.18
P/E Ratio
N/A
★ N/A
Revenue Growth
33.33
★ 52.46
52 Week Low
$20.23
$16.40
52 Week High
$38.26
$63.79

Technical Indicators

Market Signals
Indicator
BEAM
OUST
Relative Strength Index (RSI) 55.77 39.07
Support Level $25.29 $27.35
Resistance Level $28.87 $30.24
Average True Range (ATR) 1.47 2.08
MACD 0.47 -0.02
Stochastic Oscillator 55.38 21.20

Price Performance

Historical Comparison
BEAM
OUST

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About OUST Ouster Inc.

Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and the Pacific, Europe, the Middle East, and Africa. It derives maximum revenue from the Americas. The Company operates as one reportable and operating segment, which relates to the sale and production of lidar sensor kits.

Share on Social Networks: